Rubio-Guerra AF, Durán-Salgado MB

Language: Spanish
References: 19
Page: 581-584
PDF size: 133.88 Kb.

ABSTRACT

Beyond its metabolic effects, insulin has several actions on the vasculature, under normal conditions, insulin maintains a normal endothelial function, but in the presence of insulin resistance, insulin leads to endothelial dysfunction. Insulin releases nitric oxide, which promotes an antiatherosclerotic, antiinflamatory and vasodilator state. However, in presence of high levels of angiotensin II, insulin activates pathways that lead to atherosclerosis, vasoconstriction and inflammation. We will review the actions of insulin on the vascular system, and its interactions with other vasoactive mediators as angiotensin II and endothelin-1.

REFERENCES

1. Rosas-Peralta M, Lara-Esqueda A, Pastelín-Hernández G, Velázquez-Monroy O, Martínez-Reding J, Méndez-Ortiz A, et al. Re-encuesta Nacional de Hipertensión Arterial. Consolidación Mexicana de los Factores de Riesgo Cardiovascular. Cohorte Nacional de Seguimiento. Arch Cardiol Mex 2005;75:96-111.

2. Cordero A, Moreno J, Alegría E. Hipertensión arterial y síndrome metabólico. Rev Esp Cardiol 2005;58 (Supl 5):38D- 45D

3. Rubio AF. Tratamiento de la hipertensión arterial en pacientes con obesidad y diabetes mellitus. En: Castro G, Godínez S, Liceaga G, editores. Obesidad. México: Alfil; 2009. p. 235-240.

4. Tikellis Ch, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004;53(4):989-997.

5. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006;119(1):102S-115S.

6. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 2001;276 (32):30392-30398.

7. Kim J, Montagnami M, Kon K, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113(15):1888-1904.

8. Rubio-Guerra AF, Vargas-Robles H, Serrano AM, Lozano- Nuevo JJ, Escalante-Acosta BA. Correlation between the levels of circulating adhesion molecules and atherosclerosis in type-2 diabetic normotensive patients. Cell Adh Migr 2009;3(4):369-372.

9. Bhargava A, Pearce D. Mechanisms of mineralocorticoid action: determinants of receptor specificity and actions of regulated gene products. Trends Endocrinol Metab 2004;15(4):147-153.

10. Funder JW. The nongenomic actions of aldosterone. Endocr Rev 2005;26(3):313-321.

11. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51(2):16-167.

12. Kraus D, Jäger J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005;37(7):455-459.

13. Tesauro M, Lantorno M, Schinzari F, Cardillo C. Vascular effects of insulin and their relation to endothelial dysfunction, insulin resistance and hypertension. Curr Hypertens Rev 2019;5(4):251-261.

14. Rubio-Guerra AF, Vargas-Robles H, Serrano AM, Vargas- Ayala G, Rodríguez-López L, Escalante-Acosta BA. Correlation between the levels of circulating adhesion molecules and atherosclerosis in hypertensive type-2 diabetic patients. Clin Exp Hypertens 2010;32(5):308-310.

15. Rubio AF. Principios del tratamiento antihipertensivo. En: Rubio AF. Hipertensión arterial México: Manual Moderno; 2005. p. 49-55.

16. Tocci G, Paneni, Palano F, Sciarretta S, Ferrucci A, Kurtz T, et al. Angiotensin-converting enzyme inhibitors, angio-tensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens 2011;24 (5):582-590.

17. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007;25(6):1105-1188.

18. Rubio-Guerra AF, Vargas-Robles H, Ramos-Brizuela LM, Escalante-Acosta BA. Is tetrahydrobiopterin a therapeutic option in diabetic hypertensive patients. Integr Blood Press Control 2010;3:125-132.

19. Rubio-Guerra AF, Vargas-Robles H. Vargas-Ayala G. Rodríguez- Lopez L. Escalante-Acosta BA. The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens 2008;30(7):682-688.